Thompson Investment Management Inc. Buys 12,474 Shares of Abbott Laboratories $ABT

Thompson Investment Management Inc. raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 786.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 14,061 shares of the healthcare product maker’s stock after purchasing an additional 12,474 shares during the period. Thompson Investment Management Inc.’s holdings in Abbott Laboratories were worth $1,276,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in ABT. Freemont Management S.A. lifted its stake in Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after purchasing an additional 7,100 shares during the last quarter. PFA Pension Forsikringsaktieselskab purchased a new position in shares of Abbott Laboratories in the fourth quarter worth about $116,580,000. Thrivent Financial for Lutherans lifted its stake in shares of Abbott Laboratories by 24.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after acquiring an additional 48,286 shares during the last quarter. Aureus Asset Management LLC boosted its holdings in Abbott Laboratories by 25.0% during the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock valued at $34,078,000 after acquiring an additional 66,422 shares during the period. Finally, Concurrent Investment Advisors LLC grew its position in Abbott Laboratories by 23.9% during the 4th quarter. Concurrent Investment Advisors LLC now owns 88,784 shares of the healthcare product maker’s stock worth $11,124,000 after acquiring an additional 17,137 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Wells Fargo & Company boosted their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. TD Cowen reissued a “buy” rating and set a $115.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Robert W. Baird began coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target on the stock. Finally, Evercore decreased their price objective on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $118.67.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Wolfe Research upgraded Abbott Laboratories (ABT) from “peer perform” to “outperform” and set a $130 target, implying substantial upside from recent trading levels. Benzinga analyst upgrade report
• Positive Sentiment: Abbott’s Established Pharmaceutical Products division is benefiting from emerging-market growth, broad branded-generic offerings and resilient healthcare demand. Expanding biosimilar opportunities could provide an additional long-term growth avenue. Zacks EPD growth report
• Positive Sentiment: Abbott and Google Health announced a multiyear partnership to integrate Abbott’s Lingo continuous glucose-monitoring data into Google’s AI-powered consumer health tools. The collaboration could increase Lingo’s visibility, support personalized metabolic-health services and generate valuable real-world data. Abbott and Google Health Lingo partnership
• Positive Sentiment: Bank of America Securities issued a “buy” recommendation for ABT, reinforcing the constructive Wall Street view. Bank of America buy rating
• Neutral Sentiment: Abbott’s stock outperformed competitors during a strong broader trading session, reflecting market momentum but not a new company-specific fundamental catalyst. MarketWatch trading report
• Neutral Sentiment: Abbott’s PULSE study is evaluating earlier treatment for atrial fibrillation. Positive clinical results could expand future device demand, but the study remains ongoing and carries execution and clinical risk. TipRanks PULSE study report
• Neutral Sentiment: Abbott renewed its blood-donation campaign with the Big Ten amid a U.S. blood shortage. The initiative supports Abbott’s brand and blood-management business, though its direct near-term financial impact is likely limited. Abbott and Big Ten blood donation campaign

Abbott Laboratories Price Performance

ABT stock opened at $111.37 on Friday. The firm has a 50-day moving average of $97.27 and a 200 day moving average of $99.75. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The company has a market cap of $192.71 billion, a P/E ratio of 36.04, a PEG ratio of 2.15 and a beta of 0.59. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.